Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #Oncology #GeriatricOncology #Oncogeriatrics #CancerCare #MedSky #OncSky #MedNews #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #Oncology #GeriatricOncology #Oncogeriatrics #CancerCare #MedSky #OncSky #MedNews #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #Oncology #CancerAwareness #CancerCare #ParaneoplasticSyndrome #PNS #MedSky #OncSky #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #Oncology #CancerAwareness #CancerCare #ParaneoplasticSyndrome #PNS #MedSky #OncSky #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #Oncology #MedSky #OncSky #CancerAwareness #InvestigationalNewDrug #IND #FDA #ClinicalTrials #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #Oncology #MedSky #OncSky #CancerAwareness #InvestigationalNewDrug #IND #FDA #ClinicalTrials #Vocabulary
#CAPP3
Lynch syndrome carriers face up to 80% lifetime CRC risk! The ongoing CAPP3 trial is exploring optimal aspirin doses for Lynch Syndrome
#Onco404 #Cancer #Kanser #ClinicalTrials #LynchSyndrome #ColorectalCancer #EndometrialCancer #Aspirin #CancerPrevention #MedSky #OncSky
#CAPP3
Lynch syndrome carriers face up to 80% lifetime CRC risk! The ongoing CAPP3 trial is exploring optimal aspirin doses for Lynch Syndrome
#Onco404 #Cancer #Kanser #ClinicalTrials #LynchSyndrome #ColorectalCancer #EndometrialCancer #Aspirin #CancerPrevention #MedSky #OncSky
#Onco404 #Cancer #Kanser #PrecisionOncology #ClinicalTrials #TumorProfiling #MedSky #OncSky #ASCO2025
#Onco404 #Cancer #Kanser #PrecisionOncology #ClinicalTrials #TumorProfiling #MedSky #OncSky #ASCO2025
@natureportfolio.nature.com
#Onco404 #Cancer #Kanser #PrecisionOncology #ClinicalTrials #TumorProfiling #MedSky #OncSky #ASCO2025
@natureportfolio.nature.com
#Onco404 #Cancer #Kanser #PrecisionOncology #ClinicalTrials #TumorProfiling #MedSky #OncSky #ASCO2025
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #MedSky #OncSky #CancerAwareness #CancerCare #Chemokine #ImmuneSystem #ImmuneResponse #TumorImmunity #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #MedSky #OncSky #CancerAwareness #CancerCare #Chemokine #ImmuneSystem #ImmuneResponse #TumorImmunity #Vocabulary
✅ Integration of NRF2 activation status and TTF-1 expression enabled robust partitioning of patients into favorable (~70%), intermediate (~13%) and poor (~17%) prognostic groups.
#Onco404
✅ Integration of NRF2 activation status and TTF-1 expression enabled robust partitioning of patients into favorable (~70%), intermediate (~13%) and poor (~17%) prognostic groups.
#Onco404
☑️ KEAP1 co-mutations were correlated with significantly shorter PFS and OS on sotorasib.
✅ NRF2 activation (often linked to KEAP1 mutations) was also associated with inferior outcomes. mPFS: 2.73 vs 7.75 months (NRF2 low)
#Onco404 #Cancer #Kanser #AkciğerKanseri #MedSky #OncSky
#NatureMedicine
#Onco404 #Cancer #Kanser #LungCancer #Sotorasib #NSCLC #Biomarkers #PrecisionOncology #KRAS #TTF1 #KEAP1 #NRF2 #NFE2L2 #MedSky #OncSky
#NatureMedicine
#Onco404 #Cancer #Kanser #LungCancer #Sotorasib #NSCLC #Biomarkers #PrecisionOncology #KRAS #TTF1 #KEAP1 #NRF2 #NFE2L2 #MedSky #OncSky
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #CancerAwareness #Cytokine #ImmuneSystem #CancerCare #Inflammation #MedSky #OncSky #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #CancerAwareness #Cytokine #ImmuneSystem #CancerCare #Inflammation #MedSky #OncSky #Vocabulary
✅ This scalable EHR-based strategy addressed clinician barriers, increased PC access without overburdening workflows, and offers a pragmatic solution for resource-limited settings.
#Onco404
✅ This scalable EHR-based strategy addressed clinician barriers, increased PC access without overburdening workflows, and offers a pragmatic solution for resource-limited settings.
#Onco404
✅ 43.9% (intervention) vs. 8.3% (control) completed PC consults (adjusted OR: 8.9) ⤴️
☑️ Systemic therapy within 14 days of death was lower in the intervention group (6.5%) compared to control (16.1%; AOR 0.3).
#Onco404 #Cancer #Kanser #Hospice #PalliativeCare #MedSky #OncSky
@JAMANetworkOpen #JAMA
#Onco404 #Cancer #Kanser #Hospice #PalliativeCare #SupportiveCare #MedSky #OncSky #Healthcare #DigitalHealth
@JAMANetworkOpen #JAMA
#Onco404 #Cancer #Kanser #Hospice #PalliativeCare #SupportiveCare #MedSky #OncSky #Healthcare #DigitalHealth
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #CancerAwareness #Hospice #YaşamSonuBakımı #PalliativeCare #PalyatifBakım #QoL #MedSky #OncSky #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #CancerAwareness #Hospice #YaşamSonuBakımı #PalliativeCare #PalyatifBakım #QoL #MedSky #OncSky #Vocabulary
⚠️ Reporting hasn’t improved since 2015. Delays mean doctors and patients often wait 6+ months
⚠️ Median latency for reporting was 1.1 months post-approval, but a quarter took over a year
#Onco404 #Cancer #Kanser
📉 50% of trials reported HRQoL data, but only 42% had it available by FDA approval.
📉 79% of approvals relied on surrogate endpoints, yet only 18% of these showed improved HRQoL.
💊 Trials with survival (OS) endpoints: 70% reported HRQoL vs. 45% for SEPs.
#Onco404 #Cancer #Kanser
#BMJ #BMJOncology
#Onco404 #Cancer #Kanser #Oncology #ClinicalTrials #FDA #QoL #HRQoL #MedSky #OncSky #PatientReportedOutcomes
#BMJ #BMJOncology
#Onco404 #Cancer #Kanser #Oncology #ClinicalTrials #FDA #QoL #HRQoL #MedSky #OncSky #PatientReportedOutcomes
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #MedSky #OncSky #PatientCenteredCare #CancerCare #QualityOfLife #QoL #PatientReportedOutcomes #PROs #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #MedSky #OncSky #PatientCenteredCare #CancerCare #QualityOfLife #QoL #PatientReportedOutcomes #PROs #Vocabulary
Trabectedin did not improve survival vs. standard chemo and had a worse safety profile. No subgroup (BRCA status, prior PARPi use) benefited more from trabectedin.
#Onco404
Trabectedin did not improve survival vs. standard chemo and had a worse safety profile. No subgroup (BRCA status, prior PARPi use) benefited more from trabectedin.
#Onco404
✅ Median overall survival (OS): 15.8 months (arm A: trabectedin) vs. 17.9 months (arm B: control).
☑️ Median progression-free survival (PFS): 4.9 vs. 4.4 months.
✅ ORR was 17.1% (arm A) vs. 21.4% (arm B), with comparable median DoR (5.62 vs. 5.66 months).
#Onco404 #MedSky #OncSky
@ascocancer.bsky.social #JCO #ASCO
#Onco404 #Cancer #Kanser #OvarianCancer #MedSky #OncSky #BRCA #BRCAness #Trabectedin #ClinicalTrials
@ascocancer.bsky.social #JCO #ASCO
#Onco404 #Cancer #Kanser #OvarianCancer #MedSky #OncSky #BRCA #BRCAness #Trabectedin #ClinicalTrials
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #MedSky #OncSky #BRCAness #HRD #BRCA1 #BRCA2 #PlatinumChemotherapy #PARPInhibitor #TargetedTherapy #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #Cancer #Kanser #MedSky #OncSky #BRCAness #HRD #BRCA1 #BRCA2 #PlatinumChemotherapy #PARPInhibitor #TargetedTherapy #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #OncoTerm #Oncology #Cancer #Kanser #CancerAwareness #Healthcare #FightCancer #MedSky #OncSky #Vocabulary
Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
#Onco404 #OncoTerm #Oncology #Cancer #Kanser #CancerAwareness #Healthcare #FightCancer #MedSky #OncSky #Vocabulary